Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorPilanci, Kezban Nur
dc.contributor.authorSaglam, Sezer
dc.contributor.authorOkyar, Alper
dc.contributor.authorYucel, Serap
dc.contributor.authorPala\\-Kara, Zeliha
dc.contributor.authorOrdu, Cetin
dc.contributor.authorNamal, Esat
dc.contributor.authorCiftci, Rumeysa
dc.contributor.authorIner\\-Koksal, Ulkuhan
dc.contributor.authorKaytan\\-Saglam, Esra
dc.date.accessioned2025-10-16T15:28:51Z
dc.date.issued2016
dc.identifier.doi10.1007/s00280-016-3067-x
dc.identifier.otherWOS:000379027200014
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/8710
dc.publisherSPRINGER
dc.sourceCANCER CHEMOTHERAPY AND PHARMACOLOGY
dc.subjectCapecitabine
dc.subjectChronomodulated chemotherapy
dc.subjectTreatment\\-naive
dc.subjectMetastatic colorectal cancer
dc.subjectPharmacokinetics
dc.titleChronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS